Literature DB >> 20717757

Isolated extramedullary relapse in childhood acute lymphocytic leukemia.

James E Jacobs1, Caroline Hastings.   

Abstract

Although the vast majority of children with acute lymphocytic leukemia attain remission with modern therapies, an unacceptably high number will suffer a disease relapse. Both the duration of remission and the site of relapse are important prognostic factors. This review focuses on leukemic relapse isolated to sites outside the bone marrow (extramedullary sites). Data from cooperative study groups as well as large single institutions are reviewed with respect to the incidence of isolated extramedullary relapse as well as the outcome following relapse. The unique anatomic and physiologic properties of the testes and the central nervous system-the two most common sites of isolated extramedullary relapse-are discussed. Finally, the evolution of leukemia therapy is reviewed, bringing into focus the goals and challenges of future therapeutic endeavors.

Entities:  

Mesh:

Year:  2010        PMID: 20717757     DOI: 10.1007/s11899-010-0063-9

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  46 in total

1.  Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia.

Authors:  K Wheeler; S Richards; C Bailey; J Chessells
Journal:  Br J Haematol       Date:  1998-04       Impact factor: 6.998

2.  Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study .

Authors:  A K Ritchey; B H Pollock; S J Lauer; Y Andejeski; J Barredo; G R Buchanan
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

3.  Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  Deepa Bhojwani; Huining Kang; Naomi P Moskowitz; Dong-Joon Min; Hokyung Lee; Jeffrey W Potter; George Davidson; Cheryl L Willman; Michael J Borowitz; Ilana Belitskaya-Levy; Stephen P Hunger; Elizabeth A Raetz; William L Carroll
Journal:  Blood       Date:  2006-07-15       Impact factor: 22.113

4.  Testicular infiltration in acute lymphoblastic leukaemia.

Authors:  H E Kay
Journal:  Br J Haematol       Date:  1983-04       Impact factor: 6.998

5.  Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

Authors:  P S Gaynon; M E Trigg; N A Heerema; M G Sensel; H N Sather; G D Hammond; W A Bleyer
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

6.  Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions.

Authors:  Rosanna Parasole; Giuseppe Menna; Nicoletta Marra; Fara Petruzziello; Franco Locatelli; Argia Mangione; Aldo Misuraca; Salvatore Buffardi; Alessandra Di Cesare-Merlone; Vincenzo Poggi
Journal:  Leuk Lymphoma       Date:  2008-08

7.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.

Authors:  J B Nachman; H N Sather; M G Sensel; M E Trigg; J M Cherlow; J N Lukens; L Wolff; F M Uckun; P S Gaynon
Journal:  N Engl J Med       Date:  1998-06-04       Impact factor: 91.245

8.  The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients.

Authors:  E Morra; M Lazzarino; E Brusamolino; G Pagnucco; C Castagnola; P Bernasconi; E Orlandi; A Corso; A Santagostino; C Bernasconi
Journal:  Cancer       Date:  1993-07-15       Impact factor: 6.860

9.  Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia.

Authors:  F M Balis; C M Lester; G P Chrousos; R L Heideman; D G Poplack
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

10.  Central nervous system treatment in childhood acute lymphoblastic leukemia. Long-term follow-up of patients diagnosed between 1973 and 1985.

Authors:  R D Gelber; S E Sallan; H J Cohen; M Donnelly; V Dalton; F Tobia; L A Clavell; N J Tarbell
Journal:  Cancer       Date:  1993-07-01       Impact factor: 6.860

View more
  6 in total

Review 1.  The Good, the Bad and the Ugly of Testicular Immune Regulation: A Delicate Balance Between Immune Function and Immune Privilege.

Authors:  Gurvinder Kaur; Kandis Wright; Saguna Verma; Allan Haynes; Jannette M Dufour
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype.

Authors:  F V Castro; O J McGinn; S Krishnan; G Marinov; J Li; A J Rutkowski; E Elkord; D J Burt; M Holland; R Vaghjiani; A Gallego; V Saha; P L Stern
Journal:  Leukemia       Date:  2012-01-23       Impact factor: 11.528

3.  A unique case of relapsed B-acute lymphoblastic leukemia/lymphoma as an isolated omental mass.

Authors:  Kanchan Kantekure; Furha Cossor; Kenneth B Miller; Monika E Pilichowska
Journal:  Case Rep Hematol       Date:  2014-10-16

4.  Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia.

Authors:  Manman Deng; Jie Zha; Zhiwu Jiang; Xian Jia; Yuanfei Shi; Peng Li; Xiao Lei Chen; Zhihong Fang; Zhiqiang Du; Bing Xu
Journal:  J Transl Med       Date:  2018-02-28       Impact factor: 5.531

5.  Class I Myosins, molecular motors involved in cell migration and cancer.

Authors:  Juan D Diaz-Valencia; Laura A Estrada-Abreo; Leonor Rodríguez-Cruz; Alfonso R Salgado-Aguayo; Genaro Patiño-López
Journal:  Cell Adh Migr       Date:  2022-12       Impact factor: 3.405

6.  Kidney and pancreatic extramedullary relapse in adult acute lymphoblastic leukemia: a case report and review of the literature.

Authors:  Leslie Skeith; Alejandro Lazo-Langner; Joy Mangel
Journal:  Case Rep Hematol       Date:  2013-08-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.